Pfizer gains another obesity asset with $2bn deal for YaoPharma’s GLP-1RA
Pfizer has confirmed another push into the obesity market in the form of a licencing deal worth up to approximately…
Metabolic Disorders
-
-
WHO backs use of GLP-1RAs for weight loss despite shortage warning
The World Health Organization (WHO) has endorsed the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for the treatment of obesity,…
-
Eli Lilly flies the pharma flag in tech-heavy $1tn market cap club
Eli Lilly’s market capitalisation hit the $1tn mark in the past week, becoming the first healthcare company in the world…
-
Eli Lilly and Novo Nordisk disown Mangoceuticals’ GLP-1RA partnership claim
Eli Lilly and Novo Nordisk have rebutted claims that they have partnered with telehealth provider Mangoceuticals, sending the online company's…
-
Sandoz CEO forecasts a Q1 or Q2 market entry for semaglutide biosimilars in Canada
Sandoz CEO Richard Saynor predicts biosimilars referencing semaglutide to enter the Canadian market in early in 2026, as the patent…
-
Rhythm forced to wait for Imcivree expansion as FDA delays decision
The US Food and Drug Administration (FDA) has extended the review period for expanded approval of Rhythm Pharmaceuticals’ Imcivree (setmelanotide)…
-
Trump hits long-term pledge as US prices of weight loss drugs slashed
President Donald Trump achieved one of his key targets in the healthcare sector, following agreements with Eli Lilly and Novo…
-
Novo Nordisk’s oral Wegovy reduces cardiovascular risk factors in obesity
Novo Nordisk’s oral therapy Wegovy (semaglutide) reduced cardiovascular risk factors in the Phase III OASIS 4 trial. Being used by…
-
Novo Nordisk and Pfizer’s bidding war for Metsera escalates despite legal threats
Novo Nordisk has raised its offer to buy out obesity biotech Metsera to $10bn as a bidding war with Pfizer…
-
Eli Lilly ramps up orforglipron production with $1.2bn Puerto Rico site expansion
Eli Lilly will invest more than $1.2bn into its manufacturing site in Puerto Rico, as the drugmaker looks to assemble…
